Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact
- PMID: 18387436
- DOI: 10.1016/j.jacc.2007.09.073
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact
Abstract
Objectives: This study sought to identify the incidence and outcome related to inappropriate implantable cardioverter-defibrillator (ICD) shocks, that is, those for nonventricular arrhythmias.
Background: The MADIT (Multicenter Automatic Defibrillator Implantation Trial) II showed that prophylactic ICD implantation improves survival in post-myocardial infarction patients with reduced ejection fraction. Inappropriate ICD shocks are common adverse consequences that may impair quality of life.
Methods: Stored ICD electrograms from all shock episodes were adjudicated centrally. An inappropriate shock episode was defined as an episode during which 1 or more inappropriate shocks occurred; another inappropriate ICD episode occurring within 5 min was not counted. Programmed parameters for patients with and without inappropriate shocks were compared.
Results: One or more inappropriate shocks occurred in 83 (11.5%) of the 719 MADIT II ICD patients. Inappropriate shock episodes constituted 184 of the 590 total shock episodes (31.2%). Smoking, prior atrial fibrillation, diastolic hypertension, and antecedent appropriate shock predicted inappropriate shock occurrence. Atrial fibrillation was the most common trigger for inappropriate shock (44%), followed by supraventricular tachycardia (36%), and then abnormal sensing (20%). The stability detection algorithm was programmed less frequently in patients receiving inappropriate shocks (17% vs. 36%, p = 0.030), whereas other programming parameters did not differ significantly from those without inappropriate shocks. Importantly, patients with inappropriate shocks had a greater likelihood of all-cause mortality in follow-up (hazard ratio 2.29, p = 0.025).
Conclusions: Inappropriate ICD shocks occurred commonly in the MADIT II study, and were associated with increased risk of all-cause mortality.
Comment in
-
Implantable cardioverter-defibrillator shocks: a double-edged sword?J Am Coll Cardiol. 2008 Apr 8;51(14):1366-8. doi: 10.1016/j.jacc.2007.12.032. J Am Coll Cardiol. 2008. PMID: 18387437 No abstract available.
-
Implantable cardioverter-defibrillator shocks and their adverse impact on patient-centered outcomes: fact or fiction?J Am Coll Cardiol. 2008 Sep 16;52(12):1037-8; author reply 1038. doi: 10.1016/j.jacc.2008.04.066. J Am Coll Cardiol. 2008. PMID: 18786489 No abstract available.
Similar articles
-
Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011. J Am Coll Cardiol. 2008. PMID: 18687248 Clinical Trial.
-
Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.Heart. 2009 May;95(9):709-14. doi: 10.1136/hrt.2008.150656. Epub 2009 Mar 11. Heart. 2009. PMID: 19282314
-
Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks.Am J Cardiol. 2006 Feb 15;97(4):544-6. doi: 10.1016/j.amjcard.2005.08.074. Epub 2006 Jan 4. Am J Cardiol. 2006. PMID: 16461053
-
Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks.Europace. 2008 Nov;10(11):1256-65. doi: 10.1093/europace/eun205. Epub 2008 Aug 15. Europace. 2008. PMID: 18708639 Review.
-
Implantable cardioverter defibrillators and their role in heart failure progression.Europace. 2009 Jun;11(6):710-5. doi: 10.1093/europace/eup091. Epub 2009 Apr 8. Europace. 2009. PMID: 19357142 Review.
Cited by
-
Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN Trial.Circ Cardiovasc Qual Outcomes. 2024 Nov;17(11):e010822. doi: 10.1161/CIRCOUTCOMES.124.010822. Epub 2024 Nov 19. Circ Cardiovasc Qual Outcomes. 2024. PMID: 39561235 Free PMC article. Clinical Trial.
-
Assessment of Antitachycardia Pacing in Primary Prevention Patients: The APPRAISE ATP Randomized Clinical Trial.JAMA. 2024 Nov 26;332(20):1723-1731. doi: 10.1001/jama.2024.16531. JAMA. 2024. PMID: 39361311 Clinical Trial.
-
Optimal Timing of Cardioverter-Defibrillator Implantation in Patients with Left Ventricular Dysfunction after Acute Myocardial Infarction.Rev Cardiovasc Med. 2022 Apr 2;23(4):124. doi: 10.31083/j.rcm2304124. eCollection 2022 Apr. Rev Cardiovasc Med. 2022. PMID: 39076214 Free PMC article.
-
Prognostic value of serum albumin in heart failure patients with cardiac resynchronization therapy.Biomark Med. 2024;18(8):363-371. doi: 10.1080/17520363.2024.2347200. Epub 2024 May 24. Biomark Med. 2024. PMID: 39041845
-
Using artificial intelligence and deep learning to optimise the selection of adult congenital heart disease patients in S-ICD screening.Indian Pacing Electrophysiol J. 2024 Jul-Aug;24(4):192-199. doi: 10.1016/j.ipej.2024.06.003. Epub 2024 Jun 11. Indian Pacing Electrophysiol J. 2024. PMID: 38871179 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
